A global biotech startup in Exosome field is getting worldwide
attention with its excellent technology and feasibility.
ExoCoBio Inc. has been named one of 'Top 4 Most Richly
is a global market research company specialized in stem cell.
ExoCoBio Inc. succeeded in series A investment totaling KRW
12.5 billion only in about 100 days from its foundation in last
April. Following this, they presented a thesis to confirm the stem
cell exosome's feasibility in atopic dermatitis improvement and
successfully completed Series B investment of KRW 30 billion
in September. It ranks 1st track record in Korea and 3rd in
World investment performance.
Moreover, August 2018, ExoCoBio Inc. launched derma-
cosmetic brand 'Celltweet' which contains ASC-EXOSOME¢â,
an ingredient applied for a patent. 'Celltweet' is a compound
word of 'cell' and 'tweet' meaning exosome, neurotransmitter
between cells, resolves various skin stresses quickly.
<BusinessNewsWire> 2018. 10.31